A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Recruiting

Phase 2

Phase 3

PovetaciceptA Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT07204275

Conditions

Primary Membranous Nephropathy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Povetacicept

Tacrolimus

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-03. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2025-10-30.